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https://doi.org/10.1016/j.ccell.2018.06.007SUMMARYOncogene-induced senescence is a potent tumor-suppressive response. Paradoxically, senescence
also induces an inflammatory secretome that promotes carcinogenesis and age-related pathologies.
Consequently, the senescence-associated secretory phenotype (SASP) is a potential therapeutic target.
Here, we describe an RNAi screen for SASP regulators. We identified 50 druggable targets whose knock-
down suppresses the inflammatory secretome and differentially affects other SASP components. Among
the screen candidates was PTBP1. PTBP1 regulates the alternative splicing of genes involved in intracel-
lular trafficking, such as EXOC7, to control the SASP. Inhibition of PTBP1 prevents the pro-tumorigenic
effects of the SASP and impairs immune surveillance without increasing the risk of tumorigenesis.
In conclusion, our study identifies SASP inhibition as a powerful and safe therapy against inflamma-
tion-driven cancer.Significance
Oncogene-induced senescence has opposing effects in cancer as it restrains tumor initiation but paradoxically can fuel the
growth of advanced tumors via a pro-inflammatory secretome. Here, we identified multiple druggable targets whose inhi-
bition suppresses inflammation without interfering with the senescence growth arrest. One of the identified candidates is
PTBP1, a regulator of alternative splicing previously shown to promote cancer proliferation and metastasis. Knockdown
of PTBP1 in vivo reduced the pro-tumorigenic effects of senescence without increasing the risk of tumor initiation. These
findings suggest that targeting the pro-inflammatory SASP is a safe and effective therapeutic strategy that can be employed
against inflammation-driven cancers such as advanced liver tumors.
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INTRODUCTION
Senescence is a stress response that limits the replication of
damaged or aging cells by implementing a stable growth arrest.
Senescent cells display profound changes in nuclear and
chromatin organization, gene expression, and cell metabolism
(Kuilman et al., 2010). Importantly, senescent cells also secrete
a complex combination of mostly pro-inflammatory factors
collectively referred to as the senescence-associated secretory
phenotype (SASP).
During early tumorigenesis, the SASP adds to the cancer-pro-
tective effects of senescence by reinforcing the growth arrest
and by signaling to the immune system to clear incipient cancer
cells (Acosta et al., 2008, 2013; Kang et al., 2011). The SASP also
contributes to tissue repair and normal development (Munoz-
Espin and Serrano, 2014). Conversely, the SASP can mediate
many of the detrimental functions of senescent cells. The secre-
tome of lingering senescent cells can promote malignancy of
nearby cells (Coppe et al., 2010), chemoresistance (Kaur et al.,
2016), and systemic inflammation associated with many age-
related diseases (Franceschi and Campisi, 2014).
Although the specific outcome depends on the context, it ap-
pears that the net effect of the SASP in advanced cancer is to
promote tumorigenesis by enhancing the proliferative and meta-
static potential of neoplastic cells, among other mechanisms
(Coppe et al., 2010). The harmful inflammation imposed by the
SASP suggests that eliminating senescent cells (Ovadya and
Krizhanovsky, 2018) or suppressing the SASP can be advanta-
geous in many pathologies and not just cancer.
Several SASP regulators have been identified, most of which
drive inflammatory responses. These include nuclear factor kB
(NF-kB), CCAAT/enhancer-binding protein b (CEBPb), p38a
MAPK (mitogen-activated protein kinase), mammalian target of
rapamycin (mTOR), mixed-lineage leukemia (MLL), GATA4,
and Brd4 (Herranz and Gil, 2018). Many of the defined pathways
that activate the SASP are by nature important senescence ef-
fectors. Consequently, to devise coherent strategies to target
the SASP care must be taken not to negate the tumor-suppres-
sive effects associated with the senescence growth arrest.
Preliminary evidence indicates that uncoupling cell arrest and
the SASP is feasible (Herranz et al., 2015; Laberge et al., 2015;
Tasdemir et al., 2016; Wall et al., 2013). Here, we aimed to iden-
tify genes that modulate the SASP without interfering with other
senescence phenotypes and assess the therapeutic potential of
inhibiting the SASP against inflammation-driven cancer.
RESULTS
A Small Interfering RNA Screen Identifies SASP
Regulators
To discover regulators of the SASP, we carried out a large-scale
small interfering RNA (siRNA) screen (Figure 1A). We used IMR90
ER:RAS, a well-characterized cellular system of oncogene-
induced senescence (OIS). Activation of RAS with 4-hydroxy-
tamoxifen (4OHT) causes IMR90 ER:RAS cells to undergo
senescence (Acosta et al., 2013). IMR90 ER:RAS cells treated
with 4OHT become growth arrested and express interleukin-8
(IL-8), IL-6, and other SASP components, as analyzed by immu-
nofluorescence (IF) or qRT-PCR (Figures 1B and S1A–S1D).86 Cancer Cell 34, 85–102, July 9, 2018We selected IL-8 and IL-6 as readouts for the screen due to their
significant induction during OIS and the relevance of these cyto-
kines in mediating SASP-related phenotypes (Acosta et al.,
2008; Kuilman et al., 2008). After monitoring the kinetics of IL-8
and IL-6 expression during OIS (Figures S1C and S1D), we
decided to carry out the screen 8 days after 4OHT induction.
Importantly, transfection of siRNAs targeting known SASP regu-
lators such as the RELA subunit of NF-kB, CEBPb, or MAPK14,
which encodes for p38a, decreased IL-8 and IL-6, as quantified
using an automated high-throughput microscopy system (Fig-
ures 1B, 1C, and S1E). We screened a ‘‘druggable genome’’
siRNA library targeting around 7,000 genes and identified 96
genes whose knockdown increased IL-8 and IL-6, and 125
genes whose knockdown downregulated IL-8 and IL-6 during
OIS (Figure 1D). We validated the siRNAs repressing the SASP
in a secondary screen using a new library containing four
siRNAs targeting each of the aforementioned 125 candidates
(Figure 1E). At least two independent siRNAs prevented the in-
duction of IL-8 and IL-6 during OIS for 84 of the 125 candidates
tested (Figures 1E and 1F).
Identifying SASP Regulators that Do Not Revert the
Senescence Growth Arrest
The siRNA screen described above identified 84 potential SASP
regulators. However, it was unclear whether knocking down
these genes reduced IL-8 and IL-6 by preventing SASP induction
specifically or by preventing senescence. Although genes
belonging to either group are of biological interest, strategies
to repress the SASP while maintaining the senescence growth
arrest are appealing to target inflammation-driven tumorigenesis
(Coppe et al., 2010; Tchkonia et al., 2013).
To identify genes that regulate the SASP without reverting the
senescence growth arrest, we assessed how the candidate
siRNAs affected OIS-mediated induction of the senescence ef-
fectors p16INK4a and p21CIP1 and of growth arrest, monitored
by IF and assessing bromodeoxyuridine (BrdU) incorporation,
respectively (Figure 2A). As controls, we transfected siRNAs tar-
geting either p16INK4a or p53 and confirmed that these siRNAs
caused downregulation of p16INK4a or p21CIP1, respectively,
and blunted the senescence growth arrest as assessed by
increased BrdU incorporation (Figures 2B [left panel] and S2A).
By using K-means clustering, we classified the SASP-repressing
siRNAs in four categories (Figures 2C and S2B). Clusters 2 and 4
encompassed siRNAs that prevented the senescence growth ar-
rest as well as induction of p16INK4a or p21CIP1, whereas those in
cluster 3 further upregulated p21CIP1 exacerbating the arrest
(Figures S2B and S2C). Importantly, cluster 1 contained
siRNAs that reduced IL-8 and IL-6 without reverting the senes-
cence response, satisfying our criteria for genes that are required
for SASP but not growth arrest (Figures 2B [right panel] and 2C).
Fifty genes grouped in this cluster (Table S1).
Although we used IL-8 and IL-6 as readouts of our screen, the
SASP comprises dozens if not hundreds of secreted factors
(Acosta et al., 2013; Coppe et al., 2010). To investigate how
the identified candidates regulate the SASP, we performed
genome-wide transcriptome profiling. We targeted 38 out of
the 50 genes found in cluster 1 with two siRNAs against each.
To organize the transcriptome data, we used a gene set consist-
ing of the SASP components induced in IMR90 cells undergoing
Figure 1. An siRNA Screen Identifies Regulators of the SASP
(A) Workflow of the SASP siRNA screen.
(B) Representative immunofluorescence (IF) images of IL-8 and IL-6 following transfection of indicated siRNAs. Scale bar, 100 mm.
(C) IF quantification. Left panel shows single-cell intensity values of IL-8 in a representative sample well of a 96-well plate seeded with cells transfected with
indicated siRNAs. Blue line denotes quantification cutoff resulting in the IL-8 percentages shown in the right panel.
(D) Screen results. Normalized IL-8 versus normalized IL-6 values for each replicate sample of the screen. Dotted lines indicate cutoffs of ±2 SD of negative
scramble controls. siRNA pools were considered ‘‘hits’’ if they showed a B score of >2 or <3, in at least 2 out of 3 replicates for both IL-6 and IL-8.
(E) Volcano plots of the secondary siRNA screen performed in IMR90 ER:RAS cells as per the workflow given in (A). Normalized percent inhibition (NPI) shown as
mean of 3 replicates. Three replicate NPI values of each sample siRNA were compared with all scramble siRNA values by unpaired Student’s t test. Eighty-four
genesmet the selection criteria depicted by lines:R2 siRNAs with an IL-8 and IL-6 NPI <0.8 and a p value of%0.05. Only siRNAs targeting the 84 genes are color
coded as ‘‘Hit siRNAs’’.
(F) Summary of SASP screen. Venn diagrams (not to scale) show number of siRNA pools passing the filter and overlap between IL-8 and IL-6.
See also Figure S1.
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OIS (Acosta et al., 2013; Herranz et al., 2015). The analysis cate-
gorized the candidate genes from cluster 1 into four different
subclusters (1.1, 1.2, 1.3, and 1.4) demonstrating differential
SASP regulation (Figures 2D, 2E, and S2D). All the candidates
analyzed prevented IL-8 and IL-6 induction and the expression
of most inflammatory SASP components clustering in group B
(in Figure 2E, compare row B with maximum SASP induction,
‘‘P’’). However, differential effects were observed on the expres-
sion of other SASP components such as transforming growth
factor b and pro-fibrotic SASP components (clustering in group
C). The summary heatmap (Figure 2E) also reveals that the
siRNAs grouped in subclusters 1.3 and 1.4 were more potent
inhibitors of the inflammatory subset of the SASP (see also Fig-
ure 2D, top right).
To validate our candidates and verify their therapeutic poten-
tial, we utilized chemical inhibitors targeting five candidates from
cluster 1 or close family members: BW-B (inhibiting ALOX5), FIPI
(inhibiting phospholipase D), JQ1 (inhibiting BET family proteins,
related to BRD8), Tautomycetin (inhibiting protein phosphatase
1), XE-991 (inhibiting Kv7 voltage-gated potassium channels),
and Torin (mTOR, positive control) (Herranz et al., 2015).
Treatment with these inhibitors blunted the induction of IL-8
and IL-6 without rescuing the senescence growth arrest (Figures
2F and S2E). Similarly, pools of four short hairpin RNAs (shRNAs)
targeting six cluster 1 genes (BRD8, PP1A, PTBP1, PTPN14,
SKP1A, and TMEM219; Figure 2G, left panel) attenuated IL-8
and IL-6 induction (Figure 2G, right panel and Figure S2F, left
panel) without reverting the growth arrest (Figures S2E
and S2F, right panels). Thus, chemical inhibitors and shRNAs
phenocopied the corresponding siRNAs, confirming that our
screen successfully identified regulators that differentially
affect SASP composition without disturbing the senescence
growth arrest.
PTBP1 Regulates the SASP without Affecting Other
Senescence Phenotypes
Among the SASP regulators identified in the screen, knocking
down the polypyrimidine tract binding protein 1 (PTBP1) had a
strong effect on the pro-inflammatory SASP. PTBP1 encodes
for a regulator of alternative splicing whose expression positivelyFigure 2. A Subset of Screen Candidates Differentially Regulates the S
(A) Workflow for the categorization of SASP-repressing siRNAs.
(B) B scores showing the effects of different siRNAs on the expression of p16 and
siRNAs targeting a gene representative of cluster 1. Data represent mean ± SD (
(C) K-means clustering of the SASP-repressing siRNAs. Heatmap of cluster 1 s
reflects the measures from one siRNA.
(D) Heatmap showing the differential regulation of SASP components by siRN
transfected with two siRNAs targeting 38 of the cluster 1 candidates. RNA-seq
components. G: growing cells including cells transfected with scramble siRNA
transfected with siRNAs targetingCEBPb and RELA (preventing the induction ofm
scramble siRNA or a siRNA targeting p16 (showing a ‘‘maximum’’ SASP induct
replicates each. Left: hierarchical cluster showing the siRNA subclusters (colo
vertically). Right: zoom-in showing the effect of siRNAs on indicated SASP group
(E) Summary heatmap derived by averaging the heatmap presented in (D) showi
(F) IL-8 IF analysis 8 days after senescence induction of IMR90 ER:RAS cells tre
control. Data represent mean ± SD (n = 3); ***p < 0.001. Comparisons with DMS
(G) Expression levels of each gene or IL-8 measured by qRT-PCR 6 days after 4OH
(Vector) or pools of four pGIPZ-based shRNAs against the indicated candidate SA
Data represent mean ± SD (n = 3); *p < 0.05, **p < 0.01, ***p < 0.001. Compariso
One-way ANOVA (Bonferroni’s test) was used in (F) and (G) to calculate statisticcorrelates with tumor growth and poor prognosis (Wang et al.,
2017; Xue et al., 2009).
To study the function of PTBP1 during OIS, we used two
independent shRNAs targeting human PTBP1. Both shRNAs
efficiently knocked down PTBP1 expression (Figures 3A and
S3A). In agreement with our data above, PTBP1 knockdown
did not prevent the growth arrest observed during OIS (Figures
3B and 3C). In fact, knockdown of PTBP1 resulted in slightly
slower proliferation of normal cells (Figures 3C and 3D). A similar
induction of senescence markers, including SA-b-galactosidase
activity, the DNA damage response, and upregulation of
p16INK4a, p21CIP1, and p53 expression was observed in senes-
cent cells irrespective of PTBP1 depletion (Figures 3E and
S3B). In contrast, PTBP1 knockdown prevented the induction
of a specific subset of SASP components that included inflam-
matory factors such as IL-8, IL-6, and IL-1a (Figure 3F).
The ability of PTBP1 depletion to dampen the SASP without
affecting other parts of the senescence program was not
restricted to RAS-induced senescence nor was it unique to
IMR90 cells. Knockdown of PTBP1 prevented SASP induction
in response to doxorubicin in IMR90 cells (Figures 3G and
S3C), irradiation in human fibroblasts (Figure S3D), and onco-
genic HER2 expression inMCF7 breast cancer cells (Figure S3E),
without reverting the growth arrest (Figures 3G, S3D, and S3E).
Moreover, PTBP1 depletion also prevented RAS-dependent
induction of IL-8 and IL-6 in cells that were incapable of undergo-
ing senescence due to p53 depletion (Figure S3F), suggesting
that PTBP1 could control inflammation in settings other than
senescence. Finally, knocking down PTBP1 in already senes-
cent cells also decreased IL-8 and IL-6 levels (Figure 3H). There-
fore, PTBP1 reduction not only prevents SASP induction but can
also inhibit the SASP once senescence has been established.
Overall, these results reveal that depletion of PTBP1 represses
the SASP without affecting other features of senescence.
PTBP1 Regulates a Pro-inflammatory SASP Subset
Affecting Its Paracrine Functions
To better understand the extent of PTBP1-mediated SASP regu-
lation, we analyzed the transcriptome of senescent cells upon
PTBP1 knockdown (Figure 4A). While senescence inductionASP without Affecting the Senescent Growth Arrest
p21 and incorporation of BrdU. Left: positive controls. Right: two independent
n = 3).
howing B-score expression for each replicate experiment (column). Each row
As targeting cluster 1 candidates. IMR90 ER:RAS cells were independently
was performed and samples clustered according to the expression of SASP
but not treated with 4OHT (no SASP induction), N: grouping senescent cells
any SASP components), Pos: cluster grouping senescent cells transfectedwith
ion). Each column represents an average of two siRNAs per gene with three
red horizontally) and the clustering of SASP components in groups (colored
s.
ng differential regulation of SASP components.
ated with indicated drugs targeting cluster 1 genes. Torin 1 was included as
O + 4OHT.
T induction of IMR90 ER:RAS cells stably infected with an empty pGIPZ vector
SP regulators. An shRNA targeting mTOR (sh_mTOR) was included as control.
ns with Vector + 4OHT.
al significance. See also Figure S2 and Table S1.
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Figure 3. The Splicing Factor PTBP1 Regulates the SASP without Affecting Growth Arrest
(A) Immunoblot of protein extracts 6 days after 4OHT induction of IMR90 ER:RAS cells infected with indicated pGIPz shRNA vectors targeting PTBP1. Vec, empty
vector.
(legend continued on next page)
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resulted in substantial changes in gene expression, only a small
set of these changed upon PTBP1 knockdown (Figure 4B).
Principal component analysis (PCA) substantiated this observa-
tion (Figure S4A), and gene set enrichment analysis (GSEA)
further confirmed that depletion of PTBP1 inhibited the SASP
without interfering with the growth arrest (Figures 4C and S4B).
Analysis of the transcriptome data found NF-kB-dependent
signatures were downregulated upon PTBP1 knockdown (Fig-
ures 4D [left panel] and S4B). We investigated whether that
reflected direct regulation of NF-kB signaling by PTBP1 or was
the result of reduced SASP disrupting the positive feedback
loop signaling needed to amplify SASP expression. To this
end, IMR90 cells bearing an NF-kB reporter (Natarajan et al.,
2014) were treated with tumor necrosis factor a (TNFa). While
knocking down RELA prevented NF-kB activation, knocking
down PTBP1 did not affect it (Figure 4D). These experiments
suggest that the inhibition of NF-kB signaling observed upon
PTBP1 knockdown is caused by the reduced SASP impairing
the NF-kB-dependent SASP autocrine loop.
Next, we cataloged the factors secreted by senescent cells
using label-free mass spectrometry (Acosta et al., 2013; Herranz
et al., 2015). We identified 60 SASP components enriched in the
conditioned media (CM) of senescent cells, and the knockdown
of PTBP1 reduced the levels of 32 (Figure 4E), including many
pro-inflammatory cytokines. We next explored how PTBP1
depletion affected different paracrine actions mediated by se-
nescent cells. First, we examined whether PTBP1 depletion
could affect paracrine senescence (Acosta et al., 2013). Naive
IMR90 cells treated with CM from senescent cells undergo
senescence and express an SASP (Acosta et al., 2013). These
effects were impaired in naive cells treated with CM from
PTBP1-depleted senescent cells (Figure 4F). Conversely, treat-
ment with senescent CM induced paracrine arrest on cells
depleted of PTBP1 but resulted in a reduced secondary SASP
(Figure S4C).
PTBP1 Knockdown Inhibits the Tumor-Promoting
Functions of the SASP
The SASP can enhance the proliferative potential of cancer cells
to promote tumor progression (Coppe et al., 2010). To investi-
gate how PTBP1 depletion affects the tumor-promoting func-
tions of the SASP, we used an experimental xenograft mouse(B) Quantification of cells positive for BrdU incorporation at indicated days after
(C) Crystal violet-stained 6-well dishes of cells fixed 12 days following 4OHT trea
(D) Quantification of BrdU incorporation 8 days after 4OHT treatment, 15 days aft
*p < 0.05, **p < 0.01, ***p < 0.001; ns, not significant. Comparisons with Vec + 4
(E) Quantification of cells positive for the senescencemarkers p16, p21, p53, and g
Data represent mean ± SD (n = 3). ***p < 0.001; ns, not significant. Comparisons
(F) Expression levels of the indicated SASP genes assessed by qRT-PCR 6 day
represent mean ± SD (n = 3); ***p < 0.001, two-way ANOVA (Dunnett’s test).
(G) IMR90 WT cells were infected with indicated pGIPZ empty vector or PTBP1 s
the indicated senescence markers 6 days after doxorubicin induction. Right: mRN
induction normalized to the Vector + doxycycline (Doxo) condition. Data represent
Vector + Doxo, two-way ANOVA (Dunnett’s test).
(H) IMR90 ER:RAS cells were transfected with two independent siRNAs targeting
Senescence establishment at day 6 was monitored by IF analysis (middle). Kn
qRT-PCR 5 days after siRNA transfection, and 10 days after senescence induc
mean ± SD (n = 3). ***p < 0.001; ns, not significant. Comparisons with si_Scramb
See also Figure S3.model that monitors the effect of senescent fibroblasts on tumor
growth (Herranz et al., 2015). We co-injected squamous cell
carcinoma 5PT cells with normal or senescent (irradiated) fibro-
blasts subcutaneously into nude mice and confirmed that the
presence of senescent fibroblasts enhanced tumor growth (Fig-
ure 5A). Depletion of PTBP1 impaired the ability of irradiated
fibroblasts to promote the growth of 5PT tumor cells in this
setting (Figures 5A, S5A, and S5B). These experiments suggest
that knocking down PTBP1 suppresses the ability of senescent
fibroblasts to promote tumor growth. However, the use of an
immunocompromised mouse model does not fully capture the
complex interactions occurring in the tumor microenvironment.
Senescent hepatocytes are present in damaged livers (Jurk
et al., 2014; Krizhanovsky et al., 2008), and during chronic liver
disease precancerous senescent hepatocytes co-exist with
readily transformed cells. A mouse model recapitulating this
interaction was recently published (Eggert et al., 2016) (Fig-
ure 5B). In this model, senescence is induced in wild-type (WT)
mouse livers by transposon-mediated transfer of oncogenic
NRAS (NRASG12V) by hydrodynamic tail vein injection. Transduc-
tion of a non-oncogenic NRAS (NRASG12V, D38A) serves as a con-
trol (Kang et al., 2011). After 4 days, hepatocellular carcinoma
cells expressing firefly luciferase are seeded in the liver of synge-
neic mice, and tumor growth can be monitored by ex vivo tumor
imaging (Figure 5B). Importantly, this model allows us to assess
the growth of orthotopic liver tumors in fully immunocompetent
mice, hence in a context more relevant to human disease.
To study the therapeutic value of targeting PTBP1,
we expressed NRASG12V, D38A, an inactive NRAS mutant
(NRASG12V, D38A) that does not induce senescence (Kang
et al., 2011), and co-expressed NRASG12V with either a neutral
shRNA (shRen, targeting Renilla luciferase) or shRNAs targeting
PTBP1 in the same vector (Figure S5C). To assess the effect
that depletion of PTBP1 in senescent hepatocytes has on
tumor growth, we seeded the syngeneic tumor cells, and
after 15 days evaluated the tumors macroscopically and by
luciferase imaging. Knockdown of PTBP1 in senescent
NRASG12V-expressing hepatocytes prevented the acceleration
of tumor growth otherwise observed in senescent livers
(NRASG12V_shRen) compared with non-senescent livers
(NRASG12V, D38A) (Figure 5C). In accordance with what we
observed in cell culture, depleting PTBP1 expression did not4OHT treatment. Data represent mean ± SD (n = 3).
tment.
er empty vector or PTBP1 shRNA infection. Data represent mean ± SD (n = 3);
OHT. One-way ANOVA (Dunnett’s test).
H2AX 6 days after 4OHT and b-galactosidase 8 days after 4OHT by IF analysis.
with Vector + 4OHT, two-way ANOVA (Bonferroni’s test).
s after 4OHT induction normalized and compared with Vector + 4OHT. Data
hRNAs and treated with doxorubicin to induce senescence. Left: IF analysis of
A analysis of the indicated genes by qRT-PCR (right) 8 days after doxorubicin
mean ± SD (n = 3). *p < 0.05, ***p < 0.001; ns, not significant. Comparisons with
PTBP1 at day 5 after senescence induction as indicated in the scheme (left).
ockdown of PTBP1 and the effect on the indicated genes was assessed by
tion (right), normalized to the si_Scramble + 4OHT condition. Data represent
le + 4OHT, two-way ANOVA (Dunnett’s test).
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Figure 4. PTBP1 Regulates a Pro-inflammatory Subset of the SASP and Its Paracrine Functions
(A) Experimental design for the global transcriptional profiling of IMR90 ER:RAS cells (6 days after 4OHT induction) presented in (B) to (D).
(B) Subset of senescence-specific transcripts affected by PTBP1 knockdown.Mean expression (average of the normalized read counts for 3 replicates) in relation
to log2 (FC) for the indicated comparison. Significantly changing genes are highlighted in red.
(C) SASP GSEA signature in PTBP1 depleted cells + 4OHT compared with cells expressing empty vector + 4OHT.
(D)NF-kBGSEAsignatures inPTBP1depletedcells+4OHTcomparedwithcells expressingemptyvector+4OHT (left).GFPanalysisat indicated timepoints following
TNFa (50 ng/mL) treatment in IMR90 cells expressing a kB reporter (kB-GFP) and transfected with indicated siRNAs (right). Data represent mean ± SD (n = 3).
(E) Mass spectrometry analysis of CM collected from IMR90 ER:RAS cells (empty vector or two PTBP1-targeting shRNAs) 6 days after senescence induction with
4OHT. Differential secretion of the listed SASP factors shown as mean (n = 3).
(F) Experimental design to assess the effect of PTBP1 loss on secreted factors responsible for inducing paracrine senescence (left). IF analysis of the senescence
markers in IMR90 cells treated for 3–4 days with CM from the indicated IMR90 ER:RAS cells. Data represent mean ± SD (n = 3); each replicate experiment
corresponds to independent generation of CM. ***p < 0.001. Comparisons with cells treated with CM from Vector + 4OHT, two-way ANOVA (Dunnett’s test).
See also Figure S4.
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inhibit senescence in the liver (Figure 5D) but significantly
reduced the expression of multiple SASP components (Fig-
ure 5E). In summary, these data provide functional proof in a
preclinical disease model of the feasibility of SASP modulation
as a strategy to attenuate tumor growth.
PTBP1 Knockdown Affects Senescence Surveillance
but Does Not Increase the Risk of Tumorigenesis
While the SASP is thought to mediate many of the detrimental
effects attributed to senescent cells during aging and cancer, it
also has protective functions. Notably, factors secreted by
senescent cells are necessary to mount a protective immune
surveillance response during tumor initiation or in response to
re-engagement of senescence in tumors (Kang et al., 2011).
Therefore, we decided to evaluate the effect of PTBP1 depletion
on the surveillance and elimination of incipient preneoplastic
hepatocytes (Figure 6A). Mice injected with NRASG12V_shPTBP1
showed lower PTBP1 expression in NRAS+ hepatocytes
compared with mice injected with NRASG12V_shRen (Figures
6B and 6C). PTBP1 depletion did not significantly alter
the percentage of proliferating NRAS+ cells (Ki67 staining) and
the SA-b-galactosidase activity was not significantly different
between NRASG12V_shPTBP1 and NRASG12V_shRen mice (Fig-
ures 6B and 6C).
Since PTBP1 knockdown in senescent hepatocytes results in
reduced SASP production (Figure 5E), we investigated how this
affects immune cell recruitment. We first carried out immunohis-
tochemistry (IHC) staining and found that the formation of
macrophage aggregates (F4/80 and MHC II staining) and the
infiltration of T cells (CD3 staining) was significantly reduced in
the livers of NRASG12V_shPTBP1 (Figures 6D, S6A, and S6B).
Next, we measured CD11b+ infiltrating immune cells using
flow-cytometry analysis (Figures S6C and S6D). This is highly
relevant since different populations of myeloid cells have been
implicated in both senescent immune surveillance (Kang et al.,
2011) and mediating the tumor-promoting effects of senescent
cells in damaged livers (Eggert et al., 2016). Consistent with pre-
vious observations (Eggert et al., 2016; Kang et al., 2011),
expression of oncogenic NRAS (NRASG12V) resulted in signifi-
cant infiltration of CD11b+ cells andmonocyte immature myeloid
cells (Mo iMC), and a slight (not statistically significant) increase
in macrophage infiltration (Figure S6E). Depletion of PTBP1
decreased the infiltration of all these immune cells, although it
was not statistically significant (Figure 6E). Macrophages can
be further subdivided in Kupffer cells and newly infiltrating mac-
rophages (Figure S6C). Although both subpopulations increased
in NRASG12V-injected livers, only the recruitment of new macro-
phages was reduced by PTBP1 knockdown, although not signif-Figure 5. PTBP1 Knockdown Inhibits the Tumor-Promoting Functions
(A) Tumor growth induced by senescent cells in a xenograft mouse model fol
monitored bymeasuring the volume at the indicated days. Graph symbols are mea
(AUC) of the tumor growth for each mice. Data represent mean ± SD (n = 7 per g
(B–E) Tumor growth in an orthotopic model of advanced liver cancer following PT
and luciferase imaging (left) and quantification of luciferase intensity (right) shown
test). (D) Representative images and quantification of SA-b-Galactosidase expre
(boxes), and lines extending to highest and lowest observation (whiskers), **p < 0.
quantification of SASP components shown as log2 (FC) between the conditions
See also Figure S5.
94 Cancer Cell 34, 85–102, July 9, 2018icantly (Figures S6F and S6G). A corollary of the impaired im-
mune infiltration upon PTBP1 knockdown would be impaired
senescent cell clearance. A reduced percentage of NRAS+ hepa-
tocytes 6 days after transduction was observedwhen comparing
NRASG12V and the senescent incapable NRASG12V, D38A control
(Figure S6H). This reduction was impaired upon PTBP1 knock-
down, as noted by an increase in the percentage of NRAS+ cells
in those mice (Figure 6F).
Next, we evaluated whether the impaired immune surveillance
caused by PTBP1 knockdown resulted in increased long-term
risk in tumorigenesis. To this end, mice were transduced
with vectors co-expressing NRASG12V and an shRNA targeting
PTBP1 (shPTBP1_43) or a neutral control shRNA (shRen;
Figure 6G, left panel). Tumor formation was monitored periodi-
cally by sonography (Figure S6I). Interestingly, knockdown of
PTBP1 did not impart an increased risk of tumor formation, but
rather resulted in increased survival and decreased tumor forma-
tion (Figures 6G and S6J). Overall, these data suggest that
therapeutic SASP modulation to treat advanced cancers is not
only effective and feasible but can also be safe, without running
the risk of tumor initiation due to bypass of lingering senescent
cells or dampened anti-tumor immunity.
Regulation of Alternative Splicing by PTBP1 Controls
the SASP
PTBP1 is an RNA binding protein whose best-characterized
function is to regulate alternative splicing (Xue et al., 2009). We
analyzed alternative splicing during OIS taking advantage of
RNA sequencing (RNA-seq) and multivariate analysis of tran-
script splicing (Shen et al., 2014). We identified 434 splicing
events significantly altered (showing a splice change of R20%)
during OIS in IMR90 cells. These included alternative 50 or 30
splice sites, mutually exclusive exons, skipped exons, and re-
tained introns (Figures 7A and S7A; Table S2). PCA of exon inclu-
sion levels of previously published datasets (Tasdemir et al.,
2016) suggested that alternative splicing occurring in RAS-
induced senescence is likely due to both senescence induction
and RAS activation, the latter being the strongest contributor
(Figure S7B).
Next, we assessed how PTBP1 depletion affected alternative
splicing during OIS. Specifically, we examined exon-skipping
events, since these are known to be regulated by PTBP1 (Xue
et al., 2009) and are themost frequent type of alternative splicing.
While increased exon skipping was observed when comparing
senescent and normal cells, knockdown of PTBP1with two inde-
pendent shRNAs in senescent cells resulted in increased exon
inclusion (Figure S7C). This is in line with PTBP1 repressing
exon inclusion (Xue et al., 2009). In addition, we detected aof the SASP
lowing PTBP1 knockdown. Left: experimental design. Middle: tumor growth
n volumes of all themice in the indicated condition. Right: area under the curve
roup). **p < 0.01, ***p < 0.001, one-way ANOVA (Bonferroni’s test).
BP1 knockdown. (B) Experimental design. (C) Representative images of livers
as mean ± SD (n = 4 mice per group). *p < 0.05, one-way ANOVA (Bonferroni’s
ssion. Scale bar: 50 mm. Plots show median (line), upper and lower quartiles
01; ns, not significant; one-way ANOVA (Bonferroni’s test). (E) qRT-PCR-based
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significant enrichment of PTBP1 RNA binding motifs around
the splice acceptor site upstream of exons whose inclusion
increased with PTBP1 depletion (Figures 7B and S7D), suggest-
ing that those events were directly regulated by PTBP1.
To investigate how alternative splicing mediated by PTBP1
affects SASP regulation, we selected the top 95 genes alterna-
tively spliced in a PTBP1-dependent manner (Figure 7C and
Table S3). To determine the alternative splicing events respon-
sible for the altered SASP caused by PTBP1 knockdown, we
devised a multi-step screening approach (Figure 7D). First, an
siRNA library targeting the 95 candidates regulated by PTBP1
was screened for SASP regulators as previously (Figure 1).
The screen identified 13 genes whose knockdown affected
IL-8 and IL-6 expression during OIS (Figure 7E). Next, we
confirmed by qRT-PCR that the splicing of 8 out of those 13
genes depended on PTBP1 (Figures S7E and S7F). Interest-
ingly, the alternative splicing of five of these genes changed
during OIS (e.g., MARK3), while this was not the case for the
others (e.g., EXOC7, Figures S7E and S7F). To verify that a
PTBP1-dependent switch in alternative splicing was respon-
sible for regulating the SASP, we designed steric hindrance
antisense oligonucleotides (AONs) to target the splicing events,
i.e., reverting the inclusion caused by PTBP1 depletion (Figures
7F, S7E, and S7F). Most of the AONs tested partially rescued
the downregulation of IL-8 and IL-6 caused by PTBP1 knock-
down (Figure 7G).
Two of the genes whose splicing most significantly affected
SASP regulation were EXOC7 and SNX14, both involved in regu-
lating different aspects of intracellular trafficking. In particular,
EXOC7 is one of the eight core subunits of the exocyst complex
that tethers post-Golgi vesicles to the plasma membrane,
mediating exocytosis (Wu and Guo, 2015). PTBP1 knockdown
regulated the switching between the ‘‘long’’ EXOC7 isoform
(EXOC7-L, including exon 7) and the ‘‘short’’ EXOC7 isoform
(EXOC7-S, lacking exon 7), and this could be partially prevented
using two different AONs (Figures 7H, S7F, and S7G). Restoring
the levels of the EXOC7-S isoform using AONs resulted in a par-
tial rescue of IL-6 and IL-8 levels (Figures 7I and S7H). Moreover,
publicly available CLIP-seq (crosslinking immunoprecipitation
sequencing) data showed that PTBP1 binds near the splice
acceptor site upstream of EXOC7 exon 7 (Figure S7I). Although
this suggests that PTBP1 directly controls EXOC7 splicing, we
cannot exclude an indirect effect. In summary, these resultsFigure 6. PTBP1 Knockdown Impairs Senescence Surveillance withou
(A–F) Senescence surveillance following PTBP1 knockdown. (A) Experimental de
expression in livers. Scale bars, 50 mm. (C) Quantification of high PTBP1-express
also shown (right). Plots show median (line), upper and lower quartiles (boxes), an
mean ± SD (n = 4). *p < 0.05; ns, not significant. Comparisonswith NRASG12V-shRe
densitometric quantification (right) of indicated immune cell markers. For MHC
formation that develops as a consequence of NRASG12V-driven senescence in
diameter (comparison shown in Figures S6A and S6B) and are depicted as black a
cells and are quantified as number of positive cells per counting area (10 mm2). Sc
NRASG12V-shRenilla, one-way ANOVA (Bonferroni’s test). (E) Quantification of in
Figures S6C and S6D. Data represent mean ± SD (n = 4); *p < 0.05. Comparisons w
of NRAS+ cells. Data represent mean ± SD (n = 4); *p < 0.05. Comparisons with
(G) Long-term tumorigenesis in WT mice upon injection with indicated transpos
curves. Right: NRASG12V_shRen (n = 10) and NRASG12V_shPTBP1 (n = 9). *p < 0
visible GFP+ tumor nodules (>1 mm, black arrows) at endpoint.
See also Figure S6.
96 Cancer Cell 34, 85–102, July 9, 2018showed that PTBP1 affects the SASP by controlling the splicing
of multiple targets, among them EXOC7.
PTBP1 Regulates Alternative Splicing of EXOC7 to
Control the SASP
Extending the OIS observations, knockdown of PTBP1 also
affected splicing of EXOC7 in other senescence types such as
doxorubicin-induced senescence (Figure S8A). Conversely,
overexpression of PTBP1 resulted in preferential expression of
the EXOC7-S isoform and SASP induction (Figures 8A and
S8B). To understand how EXOC7 isoform switching affects
SASP regulation, we ectopically expressed either EXOC7-L
(induced by depletion of PTBP1) or EXOC7-S in proliferating
and senescent IMR90 cells. In agreement with our results above,
senescent cells overexpressing EXOC7-L displayed lower SASP
than cells overexpressing EXOC7-S (Figure 8B). Moreover,
expression of the SASP-promoting EXOC7-S isoform was suffi-
cient to partially rescue the inhibition of IL-8 and IL-6 expression
caused by PTBP1 knockdown (Figures 8C and S8C).
To examine how and to what extent EXOC7 regulates the
SASP, we compared the transcriptome of senescent cells lack-
ing PTBP1 or EXOC7 (Figures 8D and S8D). PCA showed a sep-
aration between normal and senescent cells, as defined by PC1.
Interestingly, depletion of PTBP1 or, to a lesser extent, EXOC7
separated the transcriptomes from those of senescent cells (Fig-
ure S8D, right). GSEA analysis showed that, similar to PTBP1
depletion, EXOC7 knockdown was associated with downregula-
tion of SASP and NF-kB-dependent signatures (Figure S8E).
Moreover, there was a strong correlation between the effects
of EXOC7 depletion and PTBP1 depletion on downregulating
specific components of the SASP (Figure 8E).
Since EXOC7 depletion resulted in a reduced SASP, the effect
that EXOC7 splice switching has on SASP expression could be
due to differential activity. EXOC7 phosphorylation by ERK1/2
regulates exocyst assembly and activity at the plasma mem-
brane (Ren and Guo, 2012). Although ERK1/2 phosphorylation
sites are not encoded within exon 7, we observed an increased
ERK1/2-mediated phosphorylation of the EXOC7-S isoform (Fig-
ures 8F and S8F) that correlated with a distinct subcellular local-
ization of each isoform (Figure 8G). These results suggest that
expression of the EXOC7-S isoform favors EXOC7 phosphoryla-
tion and membrane localization, corresponding to increased
SASP production.t Increasing Tumorigenesis
sign. (B) Representative IF images of NRAS, PTBP1 and SA-b-galactosidase
ing or Ki67+ among NRAS+ cells by IF. Quantification of SA-b-gal expression is
d lines extending to highest and lowest observation (whiskers). Data represent
nilla, one-way ANOVA (Dunnett’s test). (D) Representative IHC images (left) and
II+ and F4/80+ areas, arrowheads indicate characteristic myeloid aggregate
the liver. Smaller aggregates are separated from larger aggregates based on
nd gray symbols, respectively. For CD3+ staining, arrowheads indicate positive
ale bar, 100 mm. Data represent mean ± SD (n = 4). *p < 0.05. Comparisons with
dicated infiltrating immune cells by flow cytometry. Gating strategy shown in
ith NRASG12V-shRenilla, one-way ANOVA (Bonferroni’s test). (F) Quantification
NRASG12V-shRenilla, one-way ANOVA (Bonferroni’s test).
on-based plasmids. Left: experimental design. Middle: Kaplan-Meier survival
.05 by log-rank (Mantel-Cox) test. Representative images of macroscopically
(legend on next page)
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To investigate whether there is a relationship between
PTBP1 expression and EXOC7 splicing in vivo, we analyzed
available gene expression data of human tissues (GTEx) (GTEx
Consortium, 2015). PTBP1 expression levels inversely corre-
lated with inclusion of EXOC7 exon 7 across different tissues
(Figure 8H). High PTBP1 expression and EXOC7 exon 7 skipping
were associated with multiple inflammation-related signatures
as well as the epithelial-to-mesenchymal transition (Figures
8I and S8G). Together these results suggest that PTBP1-
driven alternative splicing of EXOC7 can regulate inflammation
in high-turnover tissues in vivo.
Finally, we investigated whether EXOC7 can regulate SASP-
mediated phenotypes in vivo. To this end, we transduced mice
with vectors co-expressing oncogenic NRAS (NRASG12V) and a
control shRNA or shRNAs targeting PTBP1 or EXOC7 (Figures
8J [top] and S8H). Knockdown of PTBP1 or EXOC7 did not
affect senescence (Figure S8I) but resulted in increased
numbers of NRAS+ hepatocytes (Figure 8J, bottom left). Similar
to what we observed upon PTBP1 knockdown, EXOC7 deple-
tion in senescent cells affected the SASP, as exemplified by
reduced expression of CXCL5 in NRASG12V-expressing hepato-
cytes (Figures 8J [second panel from left] and S8J). The forma-
tion of macrophage aggregates (MHC II staining) and the infil-
tration of T cells (CD3 staining) were significantly reduced in
the livers of mice co-expressing NRASG12V and an EXOC7-tar-
geting shRNA (Figures 8J [right panels] and S8K). In conclusion,
alternative splicing of EXOC7 contributes to PTBP1-mediated
control of the SASP.
DISCUSSION
Although senescence protects against tumor initiation and limits
fibrosis, the aberrant presence of senescent cells can exacer-
bate age-related pathologies and cancer progression. Conse-
quently, there is growing interest in finding pharmacological
agents that suppress the deleterious effects of senescent cells.
Until now, studies have concentrated on identifying ‘‘senolytic’’
compounds: drugs that specifically kill senescent cells. Although
still ill defined, the current view holds that the SASP is respon-
sible for many of the detrimental effects caused by senescent
cells in disease. Thus, SASP inhibition has been proposed as
an alternative to senolytics for targeting the harmful effects ofFigure 7. Regulation of Alternative Splicing by PTBP1 Controls the SA
(A) Distribution of the five types of AS events detected in senescent cells compa
(B) PTBP1 RNA binding motifs across alternative exons upon PTBP1 knockdown.
target alternatively spliced exon (dark-gray box). The yellow peak represents the
repression (red line), with no role known for PTBP1 in exon splicing enhancemen
(putatively repressed, red), decreasing (putatively enhanced, blue), or not altered
for local motif enrichment in putatively repressed (red) and enhanced (blue) exon
(C) Exon-skipping events andDPSI cutoffs used for shortlisting events changing d
loss but not affected upon senescence.
(D) Strategy to link PTBP1-driven alternative splicing and SASP regulation.
(E) Ninety-five PTBP1-spliced genes were targeted with four siRNAs and screene
three replicates and cutoffs for hit selection (dotted lines). Hit siRNAs represent
(F) Experimental design of (G).
(G) IMR90 ER:RAS cells were transfected with AONs either not targeting (NC
Data represent mean ± SD (n = 4). *p < 0.05, **p < 0.01, ***p < 0.001. Compariso
(H and I) Effect of AONs targeting EXOC7 exon 7 splicing on the SASP downregula
extracts of IMR90 ER:RAS cells 5 days after 4OHT induction. (I) Representative
See also Figure S7 and Tables S2 and S3.
98 Cancer Cell 34, 85–102, July 9, 2018senescence. With this in mind, we carried out a systematic
search for SASP regulators and found 50 potential therapeutic
targets whose inhibition blunts the SASP without posing a risk
of bypassing the tumor-suppressive growth arrest. The newly
identified SASP regulators differentially modulate the various
subsets of the SASP, providing us with a toolbox for ad hoc
SASP regulation in future studies.
We focused on one of the screen candidates, the alternative
splicing factor PTBP1. Expression of PTBP1 positively correlates
with growth of various cancers and poor prognosis (Wang et al.,
2017) but had yet to be causally linked to the negative effect of
inflammation on advanced cancer. Here, we showed that deple-
tion of PTBP1 inhibited a pro-inflammatory SASP subset without
blunting growth arrest or other phenotypes associated with
senescence. Hence, PTBP1 presents a potentially powerful ther-
apeutic target for inflammation-driven cancer. Future studies will
evaluate whether it could also be used during therapy-induced
senescence or age-related disease.
One of our key findings was that PTBP1 depletion prevented
the tumor-promoting effects of the SASP. Knocking down
PTBP1 prevented tumor growth caused by the presence of
senescent cells in two tumor models. A potential caveat of tar-
geting the SASP as a tumor therapy is that it results in decreased
clearance of preneoplastic cells by the immune system. How-
ever, we did not observe an increased risk of tumorigenesis
upon PTBP1 depletion despite the reduced immune surveil-
lance. This could be explained by PTBP1 depletion not inducing
cell cycle re-entry and, if anything, exacerbating the senescence
growth arrest. This constitutes evidence in a preclinical model
that targeting the SASP can be a viable and safe therapeutic
strategy in the context of chronic liver disease. Based on the
current understanding on how the SASP contributes to different
pathologies, PTBP1 inhibition or other anti-SASP therapies
could also be used to ameliorate the detrimental effects of
chemotherapy or to treat age-related pathologies.
The main role of PTBP1 is to regulate alternative splicing by
inducing exon skipping. A three-step screen approach sug-
gested that PTBP1 regulates the SASP by controlling splicing
of a number of genes, including EXOC7. EXOC7 is part of the
exocyst complex and has been implicated in many cellular
features such as neurite outgrowth, epithelial cell polarity, cell
motility, or cell morphogenesis (Wu andGuo, 2015). In this study,SP
red with proliferating cells by RNA-seq (see Figure 4A).
Top: scheme. Motifs are mapped to potential regulatory sequences around the
area of predicted enrichment of PTBP1 binding responsible for exon splicing
t (dashed blue line). Middle: motif density for exons with inclusion increasing
(not regulated, gray) upon PTBP1 knockdown. Bottom: statistical significance
s.
ue to loss of PTBP1. A stricter cutoff was used for events changing upon PTBP1
d for IL-8 and IL-6 regulators as described in Figure 1. NPI shown as mean of
siRNAs targeting genes scoring with R2 siRNAs in both readouts.
) or targeting the indicated exons. IF analysis of IL-6 (left) and IL-8 (right).
ns with NC, si_PTBP1_5 + 4OHT, one-way ANOVA (Dunnett’s test).
tion caused by PTBP1 knockdown. Timeline as in (F). (H) Immunoblot of protein
IF images of IL-8 8 days after 4OHT induction. Scale bar, 100 mm.
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we demonstrated how EXOC7 also regulates SASP induction.
Although the role of the exocyst complex in senescence is still
unclear, we postulate that regulation of EXOC7 splicing can
affect exocyst activity and can be exploited as a strategy to
repress the SASP. Targeting alternative splicing in disease is
gaining traction. Strategies employing CRISPR/Cas9 or adminis-
tration of AONs to induce splice switching have been successful
in improving muscular dystrophy and spinal muscular atrophy
both in mouse models and in clinical trials (Nelson et al., 2016;
Wan and Dreyfuss, 2017).
In summary, we identified 50 genes whose knockdown specif-
ically inhibits the SASP without affecting the senescence growth
arrest. One of those genes was PTBP1, a regulator of alternative
splicing. Validating the rationale of our screen, knockdown of
PTBP1 suppresses the tumor-promoting effects of the SASP
without reverting growth arrest in a preclinical model of
advanced liver cancer, suggesting that SASP modulation can
be a safe way to target inflammation-driven cancers.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Lines
IMR90, MCF7 Tet-Off and HFFF2 were cultured in DMEM (Gibco) supplemented with 10% fetal bovine serum (Sigma) and 1%
antibiotic-antimycotic solution (Gibco). MEFs were cultured in GMEM (Sigma) and 1% antibiotic-antimycotic solution (Gibco).
HNSCC cell line 5PT was cultured in keratinocyte growth medium (KGM).
To generate IMR90 cells expressing ER:RASG12V, miR30-based shRNAs (pGIPz) or kB-GFP (pTR-mCMV-copGFP), and
MEFs expressing miRE-based shRNAs, retroviral and lentiviral infections were carried out as previously described (Aarts
et al., 2017). To generate IMR90 ER:RASG12V cells expressing two miR30-based shRNAs simultaneously, viruses were mixed
at a 1:1 ratio. To generate MCF7 Tet-Off cells expressing the carboxy-terminal fragment of HER2, known as ‘p95HER2’ or
‘611CTF’, under the control of a Tet-responsive element, MCF7 cells were infected with the appropriate viruses. To generate
IMR90 PTBP1 Tet-ON or IMR90 ER:RAS EXOC7 Tet-ON, cells were infected with equal amounts of iCMV-tight and
rtTA3 viruses. To select cells that efficiently integrated both constructs the cells were treated with 0.8 mg/ml Puromycin and
25 mg/ml Hygromycin.
To induce OIS, IMR90 ER:RAS cells were treated with 100 nM 4-hydroxytamoxifen (4OHT; Sigma) reconstituted in DMSO or
MCF7 Tet-Off/p95HER2 were depleted of 1 mg/ml doxycycline (dox; Sigma). To induce chemotherapy-induced senescence,
IMR90 cells were treated with 0.4 mMdoxorubicin (Sigma) for 24 hr which was subsequently removed bymedia change until analysis
timepoint. To induce expression of PTBP1 or EXOC7, cells were treated with 100 and 12 ng/ml Doxycyline (Sigma), respectively,
added on the day of 4OHT induction.
Mice
For xenograft experiments, 1x106 5PT cells ± 3x106 IMR-90 were re-suspended in 150ml of serum free DMEM; 100ml of this mix was
injected subcutaneously into the flank of partially immunocompromised B6.129S7-Rag1tm1Mom/J (Rag1-/-) female mice (5-6 months
old) as previously described (Herranz et al., 2015). Tumor size was measured using an electronic calliper and calculated using the
formula 4p/3 x r3 (radius (r) calculated from the average diameter, measured as the tumor width and length). Optical imaging was
performed using the IVIS SpectrumCT system. All animal work followed institutional guidelines of the University of Southampton
(UK) and has been approved by UK legal authorities.
For hepatocyte senescence experiments, 4-6-week old female C57BL/6 mice were purchased from Charles River (Sulzfeld,
Germany). Intrahepatic delivery of a transposon-based plasmid pCaNIG-shRNA allowing co-expression of NRASG12V and miR30-
based shRNAs together with an expression plasmid for sleeping beauty 13 was performed via hydrodynamic tail vein injection
(HDTV) as described previously (Kang et al., 2011). For the short-term tumorigenesis study, seeding of luciferase-expressing
hepatocellular carcinoma RIL175 cells in senescent livers 4 days post-HDTV was achieved by intrasplenic injection as previously
described (Eggert et al., 2016). For immune surveillance analysis by immunohistochemistry, mice were sacrificed 6 days after
HDTV and livers were collected and either 10% formalin-fixed, paraffin embedded, or embedded in OCT compound (Tissue-Tek)
and frozen. For tumorigenesis assessment 15 days after RIL175-cell seeding, livers were explanted and incubatedwith firefly luciferin
(Biosynth) at a concentration of 0.381 mg/ml for 10 min at room temperature. Livers were consequently imaged with AEQUORIA
MDS (Hamamatsu Photonics, Hamamatsu, Japan). In the long-term study, the livers were monitored by ultrasound and mice
were sacrificed when termination criteria were fulfilled. All animal work followed institutional guidelines of T€ubingen University and
has been approved by German legal authorities.e4 Cancer Cell 34, 85–102.e1–e9, July 9, 2018
METHOD DETAILS
Vector Construction
pLNC-ER:RAS has been previously described (Acosta et al., 2008). pGIPZ-based shRNA vectors were obtained from Sigma.
pTR-mCMV-kB-copGFP and empty vector were a gift from Venkatesh Natarajan. To generate the pCANIG-mirE-based shRNA
targetingmouse PTBP1, first themiR30-based shRNA from the pGIPZ vector V3LMM_509343was converted tomiRE-based shRNA
by PCR amplification using the primers miRE-Xho-short-fw and miRE-EcoPlasmid-Rev. For de novo generation of miRE-based
shRNAs, the 97-mer oligonucleotides mousePTBP1.891 and mouseEXOC7.1546 were PCR amplified using the primers miRE-
Xho-fw and miRE-EcoOligo-rev and cloned into the pRRL lentiviral backbone SGEP. The miRE-based shRNAs were then shuttled
into the transposon plasmid pCaNIG-shRNA using XhoI and MluI fragments. 97-mers were as follows:PTBP1.891: TGCTGTTGACAGTGAGCGACAGTCTCAATGTCAAGTACAATAGTGAAGCCACAGATGTATTGTACTT
GACATTGAGACTGGTGCCTACTGCCTCGGA
EXOC7.1546: TGCTGTTGACAGTGAGCGACGCCATCTTCCTACACAACAATAGTGAAGCCACAGATGTATTGTTGTG
TAGGAAGATGGCGCTGCCTACTGCCTCGGATo generate a Tet-ON/PTBP1 expressing vector, first, full-length cDNA encoding PTBP1 (NM_002819.4) was PCR amplified from
pBABE-PTBP1 vector custom-synthesised by GenScript, using primers CMVPTBP1F (5’-CGTTCGAAGCCACCATGGACGG
CATTGTCCCA-3’) and CMVPTBP1R (5’-CCGGTTTAAACCTAGATGGTGGACTTGGAGAAG-3’), and the Platinum PCR SuperMix
High Fidelity (Invitrogen) according to manufacturer’s instructions. The PTBP1 amplicon was then shuttled into the pLenti-CMV-tight
inducible (iCMV-tight) vector using BstBI and PmeI fragments. A MCS linker had previously been introduced in place of the eGFP
in the iCMV-tight vector. The iCMV-tight and the pLenti-CMV-rtTA3 (reverse tetracycline controlled transactivator) plasmids were
purchased from Addgene (w771-1 and w785-1, respectively).
To generate a Tet-ON/EXOC7 expressing vector, EXOC7 short and long isoforms were cloned in the iCMV-tight vector. First,
EXOC7 short and long isoforms were prepared by PCR amplification using the EXOC7cloningF (5’-CGTTCGAAGCCACCATGGAC
TACAAGGACGACGATGACAAGATTCCCCCACAGGAG-3’) and EXOC7cloningR (5’-CCGCCTGCAGGTCAGGCAGAGGTGTCGA
AAAGGC-3’) primers and as template the cDNA (produced with oligo-dT primers) from IMR90 cells or shPTBP1 IMR90 cells, respec-
tively. The EXOC7 amplicons were then shuttled into the iCMV-tight vector using BstBI and SbfI fragments.
Growth Assays
BrdU incorporation and colony formation assays with crystal violet were performed as previously described (Herranz et al.,
2015). Briefly, for BrdU incorporation assays, the cells were incubated with 10 mM BrdU for 16-18 hr before being fixed with
4% PFA (w/v). BrdU incorporation was assessed by Immunofluorescence and High Content Analysis microscopy. For crystal violet
staining, the cells were seeded at low density on 6-well dishes and maintained for 10-14 days in the absence or presence of 4OHT.
Upon colony formation or confluence of a control sample, the cells were fixed with 0.5% glutaraldehyde (w/v). The plates were then
stained with 0.2% crystal violet (w/v).
Inhibitor Treatments
The working concentrations of chemical compounds were determined after dose-response testing. Specifically, (+)-JQ1 at 40 nM,
BW-B 70C at 2 mM, FIPI at 1 mM, PD98059 at 20 mM (Acosta et al., 2013), Tautomycetin at 150 nM, Torin 1 at 25 nM (Herranz et al.,
2015) and XE 991 dihydrochloride at 20 mM. All chemical compounds were reconstituted in DMSO. Inhibitor treatment was initiated
simultaneously to 4OHT-induction. Drug-containing media was refreshed every 2 days by media change to prevent additive effects.
Nucleic Acid Transfections
siRNAs were purchased fromQiagen lyophilised either in a Flexitube or spotted in Flexiplates. When available, the experimentally
verified siRNA sequences were preferred. For immunofluorescence analysis, IMR90, IMR90 ER:RAS cells, or senescent IMR90
ER:RAS cells in suspension (100 ml) were reverse transfected with siRNAs on a well of a 96-well plate. The suspension media was
DMEM supplemented with 10% FBS only. The transfection mix for each sample well contained 0.1 mL DharmaFECT 1 (GE Health-
care) in 17.5 mL plain DMEM mixed with 3.6 mL siRNA 30 min prior to cell seeding. 18 hr after transfection, allowing target cells to
adhere, themediawere replacedwith fresh completemedia, containing 4OHTwhen appropriate. The cells were fixed at the specified
time-point with 4% PFA (w/v). For mRNA analysis, the procedure was identical but scaled up 20 times to fit a 6-well plate. The cells
were harvested by scraping in 0.8 ml TRIzol RNA isolation reagent (Ambion) per well.
AONs were rationally designed using a computational approach previously described (Pramono et al., 2012), which considers
co-transcriptional binding accessibility and relevant putative splice motifs of target, and AON-to-target binding thermodynamics.
Sequences of AONs used in this study are provided in Table S4. All the designed AONs were synthesized by IDT as single-
stranded RNA bases each modified with 2’-O-methyl and phosphorothioate backbone. Forward transfection of AONs was carried
out as per siRNA transfection with the only difference being the addition of transfection mix on adhered cultures plated 3 or 4 days
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Conditioned Media (CM) Experiments
IMR90 ER:RAS cells were seeded in a 10 cm dish for each condition. The next day the media were replaced with induction media
(4OHT addition or doxycycline removal). For paracrine senescence or SASP analysis by ELISA, the media were replaced 3 days later
with DMEM supplemented with 0.5% (v/v) FBS and 1% antibiotic-antimycotic solution. 4 days later, ensuring each 10 cm dish con-
tained confluent but alive cells, the CM were collected and initially centrifuged at 2,500 rpm to remove cellular debris. The CM were
then filtered through a 0.2 mm pore size cellulose acetate membrane (Gilson). For paracrine senescence experiments, the resulting
media was mixed in a 3 to 1 ratio with DMEM supplemented with 40% (v/v) FBS. For SASP analysis by ELISA, equal volumes of CM
were used and assay performed as per manufacturer’s instructions (R&D Systems). The samples were diluted 1,000X and each
diluted sample was represented twice on the plate. The absorbance reading was taken at 450 nm (A595) in a SpectraMAX340PC
(Molecular Devices) microplate reader. Protein concentration was then estimated according to a calibration curve obtained from
the absorbance values of a dilution series of the supplied standard protein control.
For proteomic analysis of the secretome, before replacement to appropriate media on the 3rd day, the cells were washed 3 times
with pre-warmed PBS. After that, the cells were cultured for another 3 days in high glucose, no glutamine, no phenol red DMEM
supplemented with L-Glutamine (Gibco), no FBS and 4OHT where appropriate. On the 6th day, the CM were collected and
processed as mentioned above. Then the CMwere concentrated by ultracentrifugation using the Vivaspin 20 5 kDaMWCO columns
(GE Healthcare) about 100 times (Herranz et al., 2015). At this point, the protein concentration was determined using the Pierce
BCA Protein Assay Kit (Thermo Scientific). Mass spectrometry of the CM was performed as previously described (Herranz
et al., 2015).
Total RNA Extraction
Cells were scraped and homogenized in 0.8 ml TRIzol RNA isolation reagent (Ambion), mixed with 150 ml of Chloroform (Sigma),
vortexed for 15 s and centrifuged at 15,000 rpm at 4C for 30 min. After the phase separation step, the top clear RNA-containing
phase was purified using the RNAeasy Mini Kit (Qiagen) from step 2 onwards according to manufacturer’s protocol. For mouse
liver RNA extraction, harvested liver tissues were mixed with Qiazol Lysis Reagent (Qiagen) and homogenized with an electric
homogenizer. After adding chloroform samples were centrifuged and the upper phase was mixed with isopropanol to precipitate
RNA. Remaining DNA was digested with DNAseI (NEB). RNA was then purified with RNAeasy Mini Kit (Qiagen). RNA concentration
was measured using a NanoDrop ND-1000 UV-Vis spectrophotometer at an absorbance of 260 nm (A260).
cDNA Synthesis and Quantitative RT-PCR
cDNA synthesis from cell total RNA was carried out using random hexamers, unless otherwise specified, and the SuperScript II
Reverse Transcriptase (RT) kit (Invitrogen) according to manufacturer’s instructions. cDNA synthesis from mouse total RNA was
performed using PrimeScript RT Master Mix (Takara, RR036A).
For gene expression analysis, PCR amplification was performed using SYBR Green PCR Master Mix (Applied Biosystems) and
the samples were run on CFX96 Real-Time PCR Detection system (Bio-Rad). The primers were designed using PrimerBank or
Primer-BLAST to span exon-exon junctions, or to flank an intron of > 1 kb in size, to anneal to all transcript variants of the gene of
interest, and to generate a PCR product of no more than 150 bp. To calculate gene expression (‘mRNA levels’) the DDCt method
was used with the Ribosomal protein S14 (RPS14) expression as a normalizer and an untreated sample as relative control.
For alternative splicing analysis, PCR amplification was performed using Platinum PCR SuperMix High Fidelity (Invitrogen) and
the samples were run on a Dyad Peltier Thermal cycler (Bio-Rad). The primers were specifically designed to anneal to flanking exons
of the alternatively spliced exon. The PCR product was then size-resolved using Agilent 2100 Bioanalyzer and Agilent High Sensitivity
DNA Analysis Kit following manufacturer’s instructions and the bands were visualized using the 2100 Expert Software. In any given
sample, PSI (J) was calculated by the given concentration of the larger product (included exon) relative to the sum of concentrations
of both products. Sequence of primers used in this study are provided in Table S5.
For mouse SASP analysis, Real-Time-PCR was conducted using the SYBR Premix Ex Taq (Takara, RR420A) with the RT2
Profiler PCR Array Mouse Cytokines & Chemokines Kit (Qiagen, PAMM-150ZA-12) in a 7300 Real Time PCR machine (Applied
Biosystems). Data was analyzed with 7500 software (Applied Biosystems) and Data Analysis Center webtool (Qiagen) with the
DDCt method using the mean expression of Actb, Gapdh and Hsp90ab1 as normalizers.
RNA-Sequencing
The RNA-sequencing libraries for the shPTBP1 and siEXOC7 experiments were prepared as described previously (Tordella et al.,
2016) and were run on a Hiseq2500. For alternative splicing analysis (shPTBP1), we obtained on average 71 million 100bp paired
end sequencing reads for each replicate of each condition (average of 213 million reads per condition). For GSEA (siEXOC7) we
obtained on average 40 million single-end 50 bp reads for each sample.
The RNA-sequencing library for the siRNAs repressing the SASP (2 different siRNAs targeting each one of the 38 genes plus addi-
tional controls) was prepared following the Smart-seq2 protocol Picelli et al. (2014). siRNA transfection onto 96-wells was performed
as described above and on the day of collection the cells in each well were lysed in 50 ml of lysis buffer which was prepared according
to Smart-seq2. 2 ml of lysate was used for the following steps described in detail by (Picelli et al., 2014). The RNA-seq library
containing 272 samples was run on a Hiseq2500 using single-end 50-bp reads with a coverage depth of 2.5x106 reads per sample
in over 80% of samples.e6 Cancer Cell 34, 85–102.e1–e9, July 9, 2018
Immunofluorescence Staining of Cells
Cells were grown on 96-well plates, fixed with 4% PFA (w/v) and stained as follows. The cells were permeabilised in 0.2% Triton
X-100 (v/v) (Sigma) diluted in PBS for 10 min, blocked with 1% BSA (w/v) (Sigma) and 0.4% fish gelatin (v/v) (Sigma) for 30 min,
treated with primary antibody for 40 min, then with fluorescence labelled secondary antibody (Alexa Fluor) for 30 min and finally
treated with 1 mg/ml DAPI (Sigma) for 10 min. Primary and secondary antibodies were suspended in blocking solution.
All incubations were followed by 3 PBS washes. For SA-b-Galactosidase assessment, live cells were treated with 100 mM
9H-(1,3-Dichloro-9,9-Dimethylacridin-2-One-7-yl) b-D-Galactopyranoside (DDAOG, Molecular Probes) for 2 hr prior to PFA
fixation and subsequently stained with 1 mg/ml DAPI (Sigma) for 10 min.
Cytochemical SA-b-Galactosidase Assay
Cells were grown on 6-well plates, fixed with 0.5% glutaraldehyde (w/v) (Sigma) in PBS for 10-15 min, washed with 1 mM MgCl2 in
PBS (pH 6.0) 2-3 times and then incubated with X-Gal staining solution (1 mg/mL X-Gal, Thermo Scientific, 5 mM K3[Fe(CN)6] and
5 mM K4[Fe(CN)6]) for 16-18 hr at 37
C with gentle agitation. Bright field images of cells were taken using the DP20 digital camera
attached to the Olympus CKX41 inverted light microscope. The percentage of SA-b-Gal positive cells was estimated by counting
at least 200 cells per replicate sample facilitated by the ‘point picker’ tool of ImageJ software.
Staining of Tissue Sections
Sections (2-4 mm) of paraffin-embedded mouse liver were processed for IF analysis, IHC or RNA in situ hybridization. For IF, antigen
retrieval was carried out with 10 mM sodium citrate (pH 6) for 20 min in a steamer, after which sections were treated with Protein
Block (Dako) for 10 min, incubated with primary antibody O/N at 4C, incubated with fluorescence labeled secondary antibody
(Alexa Fluor) for 1 hr and finally mounted in FluoroMount-G. Primary and secondary antibodies were suspended in Antibody
Diluent (Dako).
For colorimetric-based IHC, antigen retrieval was carried out with EDTA or sodium citrate buffer, after which sections were incu-
batedwith antibodies against antigens in BONDTMprimary antibody diluent (AR9352, Leica Biosystems). Primary antibody exposure
was followed by secondary antibody (Leica Biosystems) and staining using the Novolink DAB (Polymer) kit (RE7230-K, Leica
Biosystems). Brightfield images were captured using a Leica DM 1000 LEDmicroscope and processed using Leica Application Suite
software (Leica Biosystems).
RNA in situ hybridization in 5 mm liver sections was carried out using the RNAscope 2.5 Assay (FFPE and 2.5 HD Brown Assay)
from Advanced Cell Diagnostics, according tomanufacturer’s protocol. Probes forCxcl5 (Cat#467448), the housekeeping gene Ppib
(positive control, Cat#313911) and the bacterial gene dapB (negative control, Cat#310043) were purchased from Advanced Cell
Diagnostics. Signal detection was carried out by DAB staining. Slides were counterstained with haematoxylin prior to mounting
and then whole digital slides were acquired using the Leica SCN400 scanner (Leica) at X20 magnification.
For SA-b-Galactosidase assessment, frozen sections (6 mm) were fixed in ice-cold 0.5% glutaraldehyde (w/v) solution for 15 min,
washed 2 times in 1mMMgCl2/PBS (pH 6.0) for 5min, then incubatedwith X-Gal staining solution (1mg/mLX-Gal, ThermoScientific,
5 mM K3[Fe(CN)6] and 5 mM K4[Fe(CN)6]) for 16-18 hr at 37
C, washed 2 times in distilled water, counterstained with eosin for 30 s,
dehydrated and mounted in VectaMountTM. Quantification was performed as previously described (Tordella et al., 2016).
High Content Analysis (HCA)
IF imagingwas carried out using the automated high-throughput fluorescentmicroscope INCell Analyzer 2000 (GEHealthcare) with a
20x objective with the exception of DNA damage foci analysis which required a 40x objective. Fluorescent images were acquired for
each of the fluorophores using built-in wavelength settings (‘DAPI’ for DAPI, ‘FITC’ for AlexaFluor 488 FITC, ‘Texas Red’ for
AlexaFluor 594 and ‘Cy5’ for DDAOG). Multiple fields within a well were acquired in order to include a minimum of 1,000 cells
per sample-well. HCA of the images were processed using the IN Cell Investigator 2.7.3 software as described previously (Herranz
et al., 2015). Briefly, DAPI served as a nuclear mask hence allowed for segmentation of cells with a Top-Hat method. To detect cyto-
plasmic staining in cultured cells, a collar of 7-9 mm around DAPI was applied. To detect cytoplasmic staining in tissue sections, a
multiscale top-hat parameter was set on the reference wavelength (typically NRAS staining). Nuclear IF in the reference wavelength,
i.e. all the other wavelengths apart fromDAPI, was quantitated as an average of pixel intensity (grey scale) within the specified nuclear
area. Cytoplasmic IF in the reference wavelength was quantitated as a coefficient of variance (CV) of the pixel intensities within the
collar area. Nuclear foci IF in the reference wavelength was quantified as n number of foci per nucleus. In samples of cultured cells, a
threshold for positive cells was assigned above the average intensity of unstained or negative control sample unless otherwise spec-
ified. In tissue sections, a threshold for positive cells was assigned above background staining using the built-in ‘cell to background
ratio’ measurement. Immunohistochemistry imaging and quantification was also automated.
FACS
The liver was chopped into small1 mm3 pieces and then enzymatically digested in a medium composed of equal volume of DMEM
and HBS supplemented with 0.5 mg/ml Collagenase (Serva Collagenase NB 4G) for 30 min at 37C. The enzymatic reaction was
stopped using cold medium and the liver suspension was meshed through a 70 mm nylon mesh (Falcon). After centrifugation eryth-
rocytes were lysed using an ACK buffer (150mMNH4Cl, 10mMKHCO3, and 0.1 mMEDTA). 106 cells were resuspended in blocking
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cytometer (BD Biosciences). Samples were gated on viable leukocytes by DAPI exclusion and doublets were excluded using height
versus area dot plots. Gating strategies were described previously (Eggert et al., 2016) and depicted in Figure S6. Data analysis was
performed using FlowJo software (Tree Star).
Immunoblot and Immunoprecipitation
Cells were lysed in RIPA buffer (80 mM Tris pH 8.0, 150 mM NaCl, 1% Triton X-100, 0.5% Na-Doc, 0.1% SDS, 1mM EDTA)
supplemented with 1 tablet of phosphatase and 1 tablet of protease inhibitors (Roche) per 10 ml RIPA. Lysis was performed on
ice for 20 min with occasional vortexing followed by centrifugation at 15,000 rpm at 4C for 15 min to collect protein extracts.
Immunobloting was carried out as previously described (Herranz et al., 2015). Immunoprecipitation was performed by incubating
the lysate (equal amounts of protein) with antibody (EXOC7 sc-365825 or control IgG) for 2 hr at 4C and Dynabeads Protein A for
1 hr at 4C, before being washed 3 times in RIPA buffer and eluted in Laemmli buffer for 10 min at 95C.
siRNA Screen Analysis
The screen readouts were normalized by B-score and Normalized Percent Inhibition (NPI) using the freely available online software
found at http://web-cellhts2.dkfz.de/cellHTS-java/cellHTS2/ (Pelz et al., 2010). For NPI calculation, each sample was normalized to
the control siRNAs present in the same 96-well plate. The scramble siRNA transfected cells served as negative controls and the cells
transfected with siRNAs targeting RELA and C/EBPb served as positive controls. K-means clustering was performed using R.
Analysis of Proteomics Data
Raw files were analysed using Maxquant (Cox and Mann, 2008). Files were searched against the Swissprot human database
(downloaded on August 10th 2015). Protein sequenceswere reversed to provide a decoy database that enabled a protein and peptide
false discovery rate of 1%. Fixed modification of cysteine residues (carbamidomethylated) and variable modification of methionine
residues (oxidised) were included. Protein quantification information was produced using the label-free quantification (‘‘LFQ’’)
algorithm to enable direct comparison of protein intensity between samples. The list of proteins was then filtered down to SASP
proteins according to a previously experimentally determined list (Acosta et al., 2013). Protein measurements were then mean
normalized using the ‘scale’ function in R and visualized as heatmaps using the unsupervised hierarchical clustering option in
MultiExperiment Viewer (MeV).
Analysis of RNA Sequencing Data
RNA-seq sequencing reads were aligned to hg19 genome with TopHat using parameters ‘‘–library-type fr-firststrand’’ and using
known transcripts annotation from Ensembl gene version 70. Number of reads on exons were summarised using featureCounts
function available in rsubread R package (Liao et al., 2013). Differential expression analysis was performed using DESeq2
(Love et al., 2014; Tordella et al., 2016; Trapnell et al., 2009). PCA plots were generated using plotPCA() function from DESeq2
Bioconductor package.
To generate the heatmaps shown in Figures 2D, 2E, and S2D, we initially identified differentially expressed genes between
non-senescent conditions (in total 15 replicates) and senescent conditions (in total 6 replicates) using DESeq2 with adjusted p value
of 0.05. Differentially expressed genes were filtered for and their normalized expression values (rlog) were obtained from DESeq2.
Clustering was performed with heatmap.2 function available in gplots R package version 3.0.1 with Z-score transformed rlog values.
Summary heatmap (Figure 2E) was created using average rlog values from gene and shRNA clusters. To determine differential
alternative splicing between samples, Multivariate Analysis of Transcript Splicing (MATS) on R (Shen et al., 2014) was used. The
source-code is freely available at http://rnaseq-mats.sourceforge.net. The user-defined cut-off used for the likelihood-ratio statistical
test was assigned to 20% splicing change. Shashimi plots were generated with IGV.
Gene Set Enrichment Analysis (GSEA) of RNA-Seq Data
For each differential expression analysis comparison, genes were ranked using ‘‘wald statistics’’ obtained from DESeq2 and GSEA
was carried out on these ranked lists on all curated gene sets available in MSigDB (http://software.broadinstitute.org/gsea/msigdb).
DESeq2 independent filtering is based on mean of normalised read counts and filters out genes with very low expression level. The
SASP and OIS GSEA signatures were derived from (Acosta et al., 2013) as described before (Herranz et al., 2015; Tordella
et al., 2016).
RNA-Binding Motif Analysis
FIMO (Grant et al., 2011) was used to scan the human gene sequences for the PTBP1 RNA-binding motifs inferred by (Ray et al.,
2013). The thereby predicted occurrences were mapped to the analyzed splicing events. To generate the RNA-maps (Figures 7B
and S7D), for each comparison alternative exons were divided into those with PSIs significantly increasing upon PTBP1 knockdown
(putatively repressed), those with PSIs significantly decreasing upon PTBP1 knockdown (putatively enhanced), and those with PSIs
not altered upon PTBP1 knockdown (putatively not regulated). Statistical significance for local motif enrichment is associated with
Fisher’s exact tests for differences in motif occurrences between groups of exons within 31 bp moving windows.e8 Cancer Cell 34, 85–102.e1–e9, July 9, 2018
CLIP Data Visualization
Publically available pre-processed (i.e. genomically mapped in BED-formatted files) PTBP1 CLIP-Seq data were localized through
CLIPdb (Yang et al., 2015). Those included iCLIP and PAR-iCLIP in different samples of 293T cells (GEO accession GSE57278;
Raj et al., 2014), and HITS-CLIP on HeLa cells (GEO accessions GSE19323/GSE42701; Xue et al., 2009). A BedGraph formated
file of PTBP1 iCLIP data from HeLa cells (ArrayExpress accession E-MTAB-3108; Coelho et al., 2016) was also retrieved. The
UCSC Genome Browser (Kent et al., 2002) was used for the visualization (Figure S7I).
Cross-Tissue Analysis of PTBP1 Expression and EXOC7 Exon 7 Inclusion
The data used for these analyses were obtained from the GTEx Portal (GTEx Consortium, 2015) and dbGaP (Accession number
phs000424.v6.p1 on 2017/09/03). Gene expression was quantified from gene read counts and only genes sufficiently expressed
(sum of counts per million (CPM) across all samples > 10) were kept for further analyses. Quantile normalization of gene expression
was performed using the normalizeBetweenArrays function in limma (Ritchie et al., 2015). Splicing of EXOC7 exon 7 was quantified
from the respective exon junction reads, using the percent spliced-in (PSI) metric, as in Barbosa-Morais et al. (2012). For both gene
expression and alternative splicing analyses, samples corresponding to patient-derived cell lines and two samples with missing
values for EXOC7 exon 7 skipping quantification were excluded.
Cross-Tissue Gene Set Enrichment Analysis
Samples were separated based on their PTBP1 expression levels (cut-off set as the mean PTBP1 expression level across samples,
approximately 9005 normalized read counts) or EXOC7 exon 7 inclusion levels (cut-off set as the local density minimum separating
the two peaks of the respective bimodal PSI distribution, 0.4). Gene expression was modelled as a function of sample separation
according to PTBP1 expression or EXOC7 exon 7 inclusion using limma’s lmFit (Phipson et al., 2016). GSEA with Hallmark Gene
Sets (Liberzon et al., 2015), was run on the list of genes ordered by descending t-statistic for the subsequent differential gene
expression analysis.
QUANTIFICATION AND STATISTICAL ANALYSES
For the secondary validation siRNA screen, 3 replicate NPI values of each sample siRNAwere compared to all scramble siRNA values
by unpaired, Student’s t-test. For xenograft experiments, differences between tumor growth rates were tested for statistical signif-
icance using a 2-tailed homoscedastic t-test comparing the area under the curve (AUC) for each individual tumor within a treatment
group. For the proportions of increased exon skipping/inclusion (Figure S7B), one-sided Pearson’s chi-square tests against an
expected proportion of 0.5 were used. For alternative splicing analysis by RMATS, splicing changes with a false discovery rate
(FDR) less than 0.05 were considered statistically significant. For the rest of cell culture experiments and for mouse experiments,
significant differences were determined by one-way ANOVA or two-way ANOVA (for grouped data). Asterisks (*) always indicate
significant differences as follows. ns = not significant, * = p < 0.05, ** = p < 0.01, *** = p < 0.001. n=number of biological replicates,
unless otherwise specified.
DATA AND SOFTWARE AVAILABILITY
RNA-seq data have been deposited at the Gene Expression Omnibus under the accession numbers GSE101763 (comprising
GSE101750 and GSE101758) and GSE101766.Cancer Cell 34, 85–102.e1–e9, July 9, 2018 e9
